“Update on my protocol. I spent approx. 2 weeks with a special ChatGPT prompt to create my individual Long Covid & ME/CFS treatment plan. It’s a massive plan with a 4 week introduction phase. After that first real benefits should be visible after 3 months and long lasting benefits after around 12 months. Maybe it’s risky - but I am declining slowly anyway. So, I will give it a try. My last attempt - if this is not successful, so be it.

But as I said, I see already changes (10 days in) My Lunalae is coming back on my thumbs, my wound healing is faster, less cold hands and my skin / scalp is less itchy and better heart rate while standing.

But there are also things what I would call “side effects” like pain and additional exhaustion. But I will hang in there.

I don’t know what it will bring. But why should I wait ? For what ? When ? We are loosing our lives NOW.

I will update you regularly.”

Study in the US during the Omicron wave followed 248 metformin users over 6 months.

Starting metformin within a week of COVID reduced the risk of Long COVID or death by 53%.

Safe and inexpensive with results aligning with earlier data.

“Evusheld tx my long COVID

Evusheld is a combo of 2 long-acting monoclonal antibodies Tixagevimab/cilgavimab

in 2021 I got this tx for acute COVID infection ⬇️ Prevented me from becoming hospitalized, I felt better within 45 mins of injection & my long COVID from 2020 resolved” Thread:

“Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo.

When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15–0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59–1·64) or fluvoxamine (1·36, 0·78–2·34) compared with placebo.

There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59–1·64) or fluvoxamine (1·36, 0·78–2·34) compared with placebo.

…Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe.”

(So of course we will probably never get access to this.)

“The goal of this study is to confirm that niclosamide can solve the complex symptoms of Long COVID through multiple mechanisms such as virus suppression, inflammation suppression, and neuroprotection. We hope that the clinical trial will be successful and provide a practical treatment option for Long COVID patients, which will be historic."